Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026 held today. Key approvals included the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members. However, the motions for the extraordinary part of the meeting were not put to a vote because the required quorum was not reached.
Chris Martin, Chairman of the Board of Directors, expressed gratitude to shareholders for their trust and welcomed the newly elected board members. He also acknowledged the contributions of Patrick Langlois and Luca Benatti, who stepped down after long-standing service.
Newron is a biopharmaceutical company focused on developing innovative therapies for central and peripheral nervous system diseases. Its lead compound, evenamide, is a first-in-class glutamate modulator being developed as an add-on therapy for treatment-resistant schizophrenia (TRS) and poorly responding schizophrenia patients under the global pivotal ENIGMA-TRS Phase III program. The company has signed development and commercialization agreements with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, and with Myung In Pharm for South Korea.
Newron's first marketed product, Xadago®/safinamide, is approved for Parkinson's disease in multiple regions, including the EU, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the UAE, Japan, and South Korea. The product is commercialized by partners Zambon, Supernus Pharmaceuticals (U.S.), and Meiji Seika (Japan and key Asian territories).
For more information, visit www.newron.com. The original press release is available on www.newmediawire.com.
